X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs FRESENIUS KABI ONCO. - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS FRESENIUS KABI ONCO. NOVARTIS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 301.4 22.1 1,361.8% View Chart
P/BV x 25.7 3.1 824.9% View Chart
Dividend Yield % 1.4 0.0 -  

Financials

 NOVARTIS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    NOVARTIS
Mar-17
FRESENIUS KABI ONCO.
Mar-13
NOVARTIS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs855176 485.8%   
Low Rs66679 847.9%   
Sales per share (Unadj.) Rs219.037.7 581.2%  
Earnings per share (Unadj.) Rs19.15.1 375.0%  
Cash flow per share (Unadj.) Rs20.36.7 301.9%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs307.042.5 721.5%  
Shares outstanding (eoy) m29.96158.23 18.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.53.4 102.8%   
Avg P/E ratio x39.825.0 159.3%  
P/CF ratio (eoy) x37.518.9 197.9%  
Price / Book Value ratio x2.53.0 82.8%  
Dividend payout %52.40-   
Avg Mkt Cap Rs m22,77920,135 113.1%   
No. of employees `0000.71.2 58.5%   
Total wages/salary Rs m1,393703 198.1%   
Avg. sales/employee Rs Th9,736.25,176.2 188.1%   
Avg. wages/employee Rs Th2,066.8610.4 338.6%   
Avg. net profit/employee Rs Th849.0699.6 121.4%   
INCOME DATA
Net Sales Rs m6,5625,963 110.0%  
Other income Rs m70218 3,897.2%   
Total revenues Rs m7,2645,981 121.4%   
Gross profit Rs m2591,430 18.1%  
Depreciation Rs m36258 13.9%   
Interest Rs m7-26 -27.7%   
Profit before tax Rs m9171,216 75.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m345342 100.8%   
Profit after tax Rs m572806 71.0%  
Gross profit margin %3.924.0 16.5%  
Effective tax rate %37.628.1 133.7%   
Net profit margin %8.713.5 64.5%  
BALANCE SHEET DATA
Current assets Rs m9,7315,102 190.8%   
Current liabilities Rs m1,8302,385 76.7%   
Net working cap to sales %120.445.6 264.3%  
Current ratio x5.32.1 248.6%  
Inventory Days Days49150 32.4%  
Debtors Days Days25113 22.2%  
Net fixed assets Rs m575,148 1.1%   
Share capital Rs m141158 88.9%   
"Free" reserves Rs m9,0566,556 138.1%   
Net worth Rs m9,1966,732 136.6%   
Long term debt Rs m0952 0.0%   
Total assets Rs m11,49910,388 110.7%  
Interest coverage x128.4-45.8 -280.5%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.6 99.4%   
Return on assets %5.07.5 67.1%  
Return on equity %6.212.0 52.0%  
Return on capital %10.114.6 68.8%  
Exports to sales %074.5 0.0%   
Imports to sales %024.8 0.0%   
Exports (fob) Rs mNA4,441 0.0%   
Imports (cif) Rs mNA1,477 0.0%   
Fx inflow Rs m1295,298 2.4%   
Fx outflow Rs m1,7341,772 97.8%   
Net fx Rs m-1,6053,525 -45.5%   
CASH FLOW
From Operations Rs m-3801,274 -29.8%  
From Investments Rs m4,208-1,204 -349.4%  
From Financial Activity Rs m-3,318-196 1,692.0%  
Net Cashflow Rs m510-126 -403.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 81.0 92.6%  
Indian inst/Mut Fund % 2.0 0.3 666.7%  
FIIs % 1.6 9.6 16.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 9.1 236.3%  
Shareholders   41,647 42,599 97.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Idea Cellular Plunges 6%(12:30 pm)

After opening the day flat share markets in India are trading on a dull note and are presently trading marginally below the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jun 25, 2018 03:23 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS